

Revision date: 26-Jan-2012 Version: 2.0 Page 1 of 8

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Mitoxantrone Hydrochloride Injection

Trade Name: Mitoxantrone Injection

Synonyms: Mitozantrone Chemical Family: Mixture

Intended Use: Pharmaceutical product used as Antineoplastic agent.

2. HAZARDS IDENTIFICATION

Appearance: Aqueous sterile solution, dark blue.

Signal Word: DANGER

Statement of Hazard: May cause cancer.

May cause genetic defects.

Additional Hazard Information:

Short Term: May cause skin irritation. May cause eye irritation (based on components) .

Long Term: Animal studies indicate that this material may cause adverse effects on the the developing

fetus.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include hematological effects, kidney

effects, gastrointestinal disturbances, cardiovascular effects, liver effects, and skin reaction.

EU Indication of danger: Carcinogenic: Category 2

Mutagenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

Australian Hazard Classification

R45 - May cause cancer.

R46 - May cause heritable genetic damage. Hazardous Substance. Non-Dangerous Goods.

(NOHSC):

Material Name: Mitoxantrone Hydrochloride Injection

Revision date: 26-Jan-2012 Version: 2.0

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2 of 8

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Mitoxantrone Hydrochloride	70476-82-3	274-619-1	Xn,R21-R22; Mut. Cat.2,R46; Repr. Cat.2,R61; Canc. Cat.2,R45	0.2
Acetic acid USP - glacial	64-19-7	200-580-7	C;R35 R10	0.08

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Edetate disodium	139-33-3	205-358-3	Not Listed	*
Nitrogen, NF	7727-37-9	231-783-9	Not Listed	###
Sodium chloride	7647-14-5	231-598-3	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	###
Sodium acetate	127-09-3	204-823-8	Not Listed	**

Additional Information: * Proprietary

> ** to adjust pH ### as required

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention Eye Contact:

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Use carbon dioxide, dry chemical, or water spray. **Extinguishing Media:**

Material Name: Mitoxantrone Hydrochloride Injection

Revision date: 26-Jan-2012 Version: 2.0

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

Page 3 of 8

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and

clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA

filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Mitoxantrone Hydrochloride

Pfizer OEL TWA-8 Hr: 0.3µg/m³, Skin

Acetic acid USP - glacial

ACGIH Threshold Limit Value (TWA) 10 ppm
ACGIH Threshold Limit Value (STEL) 15 ppm
Australia STEL 15 ppm

Australia TWA 10 ppm 25 mg/m³

Austria OEL - MAKs 10 ppm 25 mg/m³

 Belgium OEL - TWA
 10 ppm

 25 mg/m³
 25 mg/m³

 Bulgaria OEL - TWA
 25.0 mg/m³

 Cyprus OEL - TWA
 25.0 mg/m²

 Cyprus OEL - TWA
 10 ppm

 25 mg/m³
 25 mg/m³

 Czech Republic OEL - TWA
 25 mg/m³

37 mg/m³

Material Name: Mitoxantrone Hydrochloride Injection Page 4 of 8 Revision date: 26-Jan-2012 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Denmark OEL - TWA 10 ppm 25 mg/m³ Estonia OEL - TWA 10 ppm 25 mg/m³ **Finland OEL - TWA** 5 ppm 13 mg/m³ 10 ppm Germany - TRGS 900 - TWAs 25 mg/m³ 10 ppm Germany (DFG) - MAK 25 mg/m³ **Greece OEL - TWA** 10 ppm 25 mg/m³ **Hungary OEL - TWA** 25 mg/m³ **Ireland OEL - TWAs** 10 ppm 25 mg/m³ Latvia OEL - TWA 10 ppm 25 mg/m³ Lithuania OEL - TWA 10 ppm 25 mg/m³ **Luxembourg OEL - TWA** 10 ppm 25 mg/m³ 10 ppm Malta OEL - TWA 25 mg/m³ **OSHA - Final PELS - TWAs:** 10 ppm 25 mg/m³ **Poland OEL - TWA** 15 mg/m³ Portugal OEL - TWA 10 ppm Romania OEL - TWA 10 ppm 25 mg/m³ Slovakia OEL - TWA 10 ppm 25 mg/m³ Slovenia OEL - TWA 10 ppm 25 mg/m³ Spain OEL - TWA 10 ppm 25 mg/m³ 5 ppm **Sweden OEL - TWAs** 13 mg/m³

Sodium chloride

Latvia OEL - TWA 5 mg/m³ 5 mg/m³ Lithuania OEL - TWA

Analytical Method: Analytical method available for Mitoxantrone Hydrochloride. Contact Pfizer Inc for further

information.

Engineering controls should be used as the primary means to control exposures. General **Engineering Controls:**

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Refer to applicable national standards and regulations in the selection and use of personal **Personal Protective Equipment:**

protective equipment (PPE).

Impervious, disposable gloves (double suggested) are recommended if skin contact with drug Hands:

product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Material Name: Mitoxantrone Hydrochloride Injection

Revision date: 26-Jan-2012 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is

possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Page 5 of 8

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:Sterile solutionColor:Dark blueMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Mitoxantrone Hydrochloride

Rat Oral LD50 682 mg/kg
Mouse Oral LD50 502 mg/kg
Rat Dermal LD50 1640 mg/kg
Rabbit Dermal LD50 125 mg/kg
Rat Intravenous LD50 4.8 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Mitoxantrone Hydrochloride

Reproductive & Fertility Rat No route specified 0.25 mg/kg LOAEL Fetotoxicity Reproductive & Fertility Rabbit Intravenous 0.5 mg/kg NOAEL Negative

Material Name: Mitoxantrone Hydrochloride Injection

Revision date: 26-Jan-2012 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Embryo / Fetal Development Rabbit No route specified 0.2 mg/kg/day NOAEL Teratogenic

Embryo / Fetal Development Rat No route specified 6 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Mitoxantrone Hydrochloride

In Vivo Cytogenetics Rat Positive

Unscheduled DNA Synthesis Rat Hepatocyte Positive

Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive

In Vitro Chromosome Aberration Hamster Positive

Somatic Mutation & Recombination Test (SMART) Drosophila Positive

Carcinogen Status: See below

Mitoxantrone Hydrochloride

IARC: Group 2B (Possibly Carcinogenic to Humans)

OSHA: Listed

At increase risk from exposure: This material has been shown to be secreted in low concentrations in human breast milk.

Women of childbearing age or nursing mothers should exercise caution regarding exposure.

Page 6 of 8

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Carcinogenic: Category 2

Mutagenic: Category 2

Material Name: Mitoxantrone Hydrochloride Injection

Revision date: 26-Jan-2012 Version: 2.0

15. REGULATORY INFORMATION

EU Risk Phrases:

R45 - May cause cancer.

R46 - May cause heritable genetic damage.

EU Safety Phrases:

S36/37 - Wear suitable protective clothing and gloves.

S45 - In case of accident or if you feel unwell seek medical advice immediately (show the label

Page 7 of 8

where possible).

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

DANGER

May cause cancer.

May cause genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Mitoxantrone Hydrochloride

California Proposition 65 developmental toxicity initial date 7/1/90

Australia (AICS): Present EU EINECS/ELINCS List 274-619-1

Acetic acid USP - glacial

CERCLA/SARA Hazardous Substances 5000 lb and their Reportable Quantities: 2270 kg Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 2 for Drugs and Poisons: Schedule 5

EU EINECS/ELINCS List Schedule 6 200-580-7

Edetate disodium

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
205-358-3

Nitrogen, NF

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present

Present

Material Name: Mitoxantrone Hydrochloride Injection Page 8 of 8
Revision date: 26-Jan-2012 Version: 2.0

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the

obligations of Register:

EU EINECS/ELINCS List 231-783-9

Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

231-598-3

Water for injection

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Sodium acetate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
204-823-8

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R21 - Also harmful in contact with skin.

R45 - May cause cancer.

R46 - May cause heritable genetic damage. R61 - May cause harm to the unborn child.

R10 - Flammable.

R35 - Causes severe burns.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 5 - Fire Fighting Measures.

Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 - Disposal Considerations. Updated Section 3 - Composition / Information on Ingredients. Updated

Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet